TAP Partner News During ASH: Dec 2024
TAP Partner News During ASH: Dec 2024
ASH Highlights (click to learn more about each TAP partnership)
-
Affimed: clinical poster presentation of AFM13 in combination with allogeneic NK cells (AlloNK) in R/R cHL
-
Celator/Jazz: multiple presentations (5 orals) on CPX-351 clinical results in AML and many poster presentations (>10)
-
Constellation/MorphoSys: clinical poster presentation of Phase 3 MANIFEST-2 updated data in treatment-naive myelofibrosis
-
Dren: oral clinical presentation of DR-01 Phase 1 trial results in cytotoxic lymphomas
-
Enterome: 2 poster presentations of EO2463, biomarker data from P1 trial and P2 data from WW FL trial (cohort 2)
-
Faron: clinical poster presentation of bexmarilimab P2 data in combo with Aza in HR-MDS
-
ImCheck: clinical poster presentation of ICT01 Phase 2 1L AML in combo with Ven/Aza
-
Immune-Onc: oral clinical presentation of IO-202 Phase 2 1L CMML in combo with Aza
-
Kite/Gilead: multiple presentations (4 oral and 4 posters) of axi-cel in a variety of B-NHL indications, including FL and LBCL
-
Kura: oral and poster clinical presentations of ziftomenib (KO-539) showcasing clinical combination studies from KOMET-7 study
-
Kymera: clinical poster presentation of STAT3 degrader in cHL and TCL (PTCL and CTCL) and preclinical poster of MDM2 degrader in AML
-
Rgenta: poster presentation of preclinical data of RGT-61159 in AML
-
Secura Bio: one oral and one poster presentation on duvelisib clinical data in TCL
-
Vittoria: one oral and one poster presentation on manufacturing platform and preclinical data to support Phase 1 trial in TCL
Company Announcements
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
MANNHEIM, Germany, Nov. 05, 2024 - Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced three abstracts on two of its innate cell engagers (ICE®) are accepted for presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. Updated clinical results from all 4 cohorts of the run-in phase from the LuminICE-203 study evaluating acimtamig (AFM13) in combination with AlloNK® (AB-101) for relapsed/ refractory Hodgkin Lymphoma will be shared in a poster session. An oral presentation will feature clinical results including promising efficacy and safety data from the AFM28 phase 1 dose escalation study in relapsed/refractory acute myeloid leukemia (AML) and poster with preclinical data will highlight the in vitro efficacy of AFM28 in combination with both patient-derived autologous NK cells and healthy volunteer-derived allogeneic NK cells against leukemic blasts.
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
Paris, France – November 6th, 2024 - Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, today announced that clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of EO2463, an experimental treatment for indolent non-Hodgkin B-cell lymphoma (iNHL), will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Conference, to take place December 7-10, 2024, in San Diego, California, and online.
Immune-Onc Therapeutics Selected for Oral Presentation at American Society of Hematology (ASH) Annual Meeting to Showcase New Data from Phase 1b Study of IO-202 in Chronic Myelomonocytic Leukemia
PALO ALTO, CA, November 5, 2024 - Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the latest data from the Phase 1b expansion cohort of its first-in-class anti-LILRB4 antibody, IO-202, in combination with azacitidine (AZA) for the treatment of chronic myelomonocytic leukemia (CMML), has been selected for an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting, to be held December 7-10 in San Diego, California.
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), will share 8 presentations, including four oral presentations, demonstrating the strength of its Yescarta (axicabtagene ciloleucel) CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
SAN DIEGO, Nov. 05, 2024 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that two abstracts highlighting clinical data from the KOMET-007 combination trial of ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, to be held in San Diego from December 7-10, 2024.
Rgenta Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
WOBURN, Mass., Nov. 5, 2024 - Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, announced today that preclinical data will be presented from its lead program, RGT-61159, at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.
Secura Bio Announces Poster Presentation Highlighting New COPIKTRA® (duvelisib) Data for the Treatment of Patients With Peripheral T-Cell Lymphoma and Other Advanced Hematologic Malignancies at the 2024 American Society of Hematology Meeting
SUMMERLIN, Nev., Nov. 06, 2024 - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announced a poster presentation highlighting new data on the investigational use of COPIKTRA® (duvelisib) both as a single agent and in combination therapy for the treatment of Peripheral T-cell Lymphoma (PTCL) and advanced hematologic malignancies at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting taking place on December 7-10, 2024 in San Diego, CA.